Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.45 |
| ▸ | TLR4 | O00206 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234471 | 0.95 | GPR119 (0.41) | TLR8TLR7TLR9TLR4GPR119 | |
| SCHEMBL25194763 | 0.88 | GPR119 (0.44) | GPR119 | |
| SCHEMBL25204635 | 0.88 | GPR119 (0.44) | TLR8GPR119 | |
| SCHEMBL25204156 | 0.88 | GPR119 (0.44) | TLR8GPR119 | |
| SCHEMBL25228603 | 0.87 | TLR8 (0.39) | TLR8TLR7TLR9GPR119PIK3CD | |
| SCHEMBL25217227 | 0.87 | GPR119 (0.42) | GPR119HPGDKDM4EALDH1A1 | |
| SCHEMBL25602218 | 0.86 | TLR8 (0.41) | TLR8TLR7TLR9TLR4GPR119 | |
| SCHEMBL24163466 | 0.84 | RIPK2 (0.39) | GPR119DDB1CRBNPIK3CD | |
| SCHEMBL25210129 | 0.84 | TLR8 (0.39) | TLR8TLR7TLR9TLR4TP53 | |
| SCHEMBL21980169 | 0.84 | TRPV3 (0.45) | TP53GPR119THRBHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097007-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | TLR8 4736/4885TLR7 4705/4885TLR9 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.